Introducing sustainable primary packaging in the pharma industry is not an easy task, especially considering the stringent regulatory and safety standards within which the sector operates. However, the market for sustainable pharmaceutical packaging is projected to grow at a compound annual growth rate (CAGR) of 15.4% to $146.3 billion by 2027. Moreover, the recent regulatory evolutions – such as the Packaging and Packaging Waste Regulation – suggest that healthcare will also be rapidly impacted by this necessary transition.
During this webinar, Claudia Monfredini, ESG Manager, and Nicola Carandente, Group Sales Director, will explain how Bormioli Pharma can facilitate this transition through its EcoPositive range, generating advantages for both pharma companies and patients. More in detail, the audience will take away:
- How to reduce your scope 3 emissions by embracing sustainable pharma packaging;
- The existing differences between all the various EcoPositive options, including advanced recycling bottles, last-generation bio-plastic containers and high-value recycled PET packaging;
- Third-party analysis results showing the exceptionally low levels of extractables contained in EcoPositive solutions.
Register to the webinar now! You’ll have the opportunity to gain a competitive advantage through sustainable pharma packaging, while reducing your company’s impact on the environment.
Key Objectives:
- Understanding the challenges and opportunities in adopting sustainable primary packaging within the pharmaceutical industry, considering regulatory and safety standards.
- Gaining an extensive knowledge of the low-impact packaging solutions existing on the market and how to implement them quickly and effectively.
- Evaluating the environmental benefits of EcoPositive solutions in reducing scope 3 emissions and enhancing sustainability profiles for pharmaceutical companies.
- Having access to scientific analysis demonstrating the safety level of EcoPositive packaging solutions.
Back
